Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Sapanisertib Market Size Analysis and Sales Forecast 2020-2034: Commercial Outlook Hinges on Late-Stage Success

globenewswire.com
TSHA Sensei Biotherapeutics announced the dosing of the first patient in a Phase Ib/II study for PIKTOR, an investigational combination therapy including sapanisertib. The company acquired Faeth Therapeutics, which contributed to this development.

Sapanisertib Market Size Analysis and Sales Forecast 2020-2034: Commercial Outlook Hinges on Late-Stage Success Dublin, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The "Sapanisertib Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.

The report delivers a comprehensive assessment of the investigational therapy's clinical development, commercial potential, competitive positioning and forecast sales across the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom and Japan.

The analysis covers potential indications including bladder cancer, endometrial cancer, fallopian tube cancer, glioblastoma, neuroendocrine tumors, ovarian cancer, peritoneal cancer, precursor cell lymphoblastic leukemia-lymphoma, soft tissue sarcoma, thyroid cancer, urogenital cancer and other selected malignancies. It includes historical analysis and market forecasts from 2020 through 2034, supported by clinical, regulatory and competitive intelligence.

Key Factors Influencing Sapanisertib Market Growth

Commercial growth remains dependent on successful late-stage development, regulatory approval and evidence of clinically meaningful benefits over established therapies such as everolimus and sirolimus. No company-endorsed peak sales estimate or commercial revenue forecast has been disclosed, and sapanisertib remains investigational.

Recent Sapanisertib Development

In May 2026, Sensei Biotherapeutics announced that the first patient had been dosed in FTH-PIK-101 (NCT07558733), a Phase Ib/II study evaluating PIKTOR in patients with HR-positive, HER2-negative advanced breast cancer. PIKTOR is an investigational all-oral combination of serabelisib and sapanisertib designed to target PI3K-alpha and mTORC1/2. The program became a lead development asset for Sensei following its acquisition of Faeth Therapeutics.

Sapanisertib Drug and Clinical Profile

Sapanisertib is an investigational, orally administered, selective dual inhibitor of mTORC1 and mTORC2. Originally developed by Takeda, the compound has been evaluated in Phase I and Phase II studies as monotherapy and in combination with targeted therapies, chemotherapy and endocrine agents.

Clinical development has included renal cell carcinoma, endometrial cancer, breast cancer, prostate cancer and acute leukemia. Reported adverse events have included hyperglycemia, stomatitis, fatigue, nausea, diarrhea and rash. Although studies have demonstrated preliminary antitumor activity and a manageable safety profile in selected settings, development has also faced challenges in establishing sufficient efficacy for late-stage advancement.

Scope of the Sapanisertib Market Report

Sapanisertib Market Forecast and Competitive Intelligence

The report evaluates the projected sapanisertib market size and revenue opportunity by indication and geography. Forecast assumptions consider eligible patient populations, clinical development probability, potential launch timing, treatment duration, pricing, reimbursement, competitive intensity and anticipated uptake.

Competitive intelligence includes pipeline analysis, comparison with existing mTOR inhibitors and assessment of emerging therapies that could influence market penetration. The analysis also examines sapanisertib's potential strengths and limitations relative to current standards of care, including efficacy, safety, administration and suitability for combination regimens.

Key Strategic Questions Addressed

Key Topics Covered

1. Report Introduction

2. Sapanisertib Overview in potential indication like Bladder cancer, Cancer, Endometrial cancer, Fallopian tube cancer, Glioblastoma, Neuroendocrine tumours, Ovarian cancer, Peritoneal cancer, Precursor cell lymphoblastic leukaemia-lymphoma, Soft tissue sarcoma, Thyroid cancer, and Urogenital cancer

2.1. Product Detail

2.2. Sapanisertib Clinical Development

2.2.1. Sapanisertib Clinical studies

2.2.2. Sapanisertib Clinical trials information

2.2.3. Safety and efficacy

2.3. Other Developmental Activities

2.4. Product Profile

3. Sapanisertib Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Sapanisertib Therapies)

5. Sapanisertib Market Assessment

5.1. Sapanisertib Market Outlook in potential indications

5.2. 7MM Analysis

5.2.1. Sapanisertib Market Size in the 7MM for potential indications

5.3. Country-wise Market Analysis

5.3.1. Sapanisertib Market Size in the United States for potential indications

5.3.2. Sapanisertib Market Size in Germany for potential indications

5.3.3. Sapanisertib Market Size in France for potential indications

5.3.4. Sapanisertib Market Size in Italy for potential indications

5.3.5. Sapanisertib Market Size in Spain for potential indications

5.3.6. Sapanisertib Market Size in the United Kingdom for potential indications

5.3.7. Sapanisertib Market Size in Japan for potential indications

6. Sapanisertib SWOT Analysis

7. Analyst's Views

8. Appendix

8.1. Bibliography

8.2. Report Methodology

List of Tables

Table 1: Sapanisertib, Clinical Trial Description, 2023

Table 2: Sapanisertib, General Description

Table 3: Competitive Landscape (Marketed Therapies)

Table 4: Competitive Landscape (Emerging Therapies)

Table 5: Sapanisertib's pricing and cost Assumptions

Table 6: Sapanisertib's Sales Analysis in the 7MM, in USD million (2020-2034)

Table 7: Sapanisertib Market Size in the US, in USD million (2020-2034)

Table 8: Sapanisertib Market Size in Germany, in USD million (2020-2034)

Table 9: Sapanisertib Market Size in France, in USD million (2020-2034)

Table 10: Sapanisertib Market Size in Italy, in USD million (2020-2034)

Table 11: Sapanisertib Market Size in Spain, in USD million (2020-2034)

Table 12: Sapanisertib Market Size in the UK, in USD million (2020-2034)

Table 13: Sapanisertib Market Size in Japan, in USD million (2020-2034)

List of Figures

Figure 1: Sapanisertib's Sales Analysis in the 7MM, USD million (2020-2034)

Figure 2: Sapanisertib Market Size in the United States, USD million (2020-2034)

Figure 3: Sapanisertib Market Size in Germany, USD million (2020-2034)

Figure 4: Sapanisertib Market Size in France, USD million (2020-2034)

Figure 5: Sapanisertib Market Size in Italy, USD million (2020-2034)

Figure 6: Sapanisertib Market Size in Spain, USD million (2020-2034)

Figure 7: Sapanisertib Market Size in the United Kingdom, USD million (2020-2034)

Figure 8: Sapanisertib Market Size in Japan, USD million (2020-2034)

For more information about this report visit https://www.researchandmarkets.com/r/6yxt1i

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.